A new method for mapping DNA methylation in cells
Official title: Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping
Funded at Epicypher, INC. · NIH-10815844 · Data updated 2026-11-12
This study is exploring a new technology to create detailed maps of how DNA changes in cells, which could help us understand diseases like cancer and brain disorders better, ultimately leading to better tests and treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Epicypher, INC. NIH-funded |
| Lab location | 1 site (Research Triangle Park, UNITED STATES) |
| Project start | February 1, 2022 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,032,776 |
| NIH project number | 5R44HG011875-03 |
| Project ID | NIH-10815844 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancers or neurological disorders who are interested in novel diagnostic and therapeutic approaches.
✕Less likely to help
Patients with conditions unrelated to DNA methylation or chromatin modifications may not receive direct benefits from this research.
What this research studies
This research focuses on developing an advanced technology called Targeted Enzymatic Methylation-sequencing (TEM-seqTM) to create detailed maps of DNA methylation patterns in cells. By utilizing innovative techniques that require fewer cells and less sequencing effort, the project aims to uncover how DNA methylation interacts with other chromatin features to regulate gene expression. This could lead to a better understanding of various diseases, including cancers and neurological disorders, by providing insights into the molecular mechanisms at play. Patients may benefit from improved diagnostic tools and targeted therapies based on these findings.
Why it matters
Potential benefit: If successful, this research could lead to more precise diagnostic tools and targeted treatments for various diseases, particularly cancers.
How similar studies have gone: Other research has shown promise in using advanced genomic mapping techniques, suggesting that this approach could yield significant insights.
Where this research is happening
-
Epicypher, INC.
Research Triangle Park, United States Active
Researchers
- Principal investigator: Keogh, Michael-Christopher — Epicypher, INC.
- Study coordinator: Keogh, Michael-Christopher
Related research
Other NIH-funded projects on the same topics.
-
New tools to map and measure epigenetic changes in aging and Alzheimer's disease
A small grant is funding new methods to find and measure combinations of chemical tags on histones that change with aging and Alzheimer’s disease, helping identify targets and biomarkers.
-
Mapping how drugs bind to chromatin to speed new therapies
A new test will map where small drug molecules touch chromatin in human cells to help design better, safer epigenetic drugs.
-
New tools to study how asymmetric histone tweaks control gene activity
A new NIH grant aims to create designer nucleosomes with asymmetric modifications to better understand how gene regulation is influenced by the histone code, which could lead to better biomarkers and therapies for cancer.
-
Epigenomic profiling of cell-free nucleosomes in plasma cancer research
A new test platform analyzes the tiny pieces of DNA wrapped around proteins in blood to help identify cancer signals.
-
Scalable single-molecule chromatin accessibility profiling in immune cells
A new approach aims to map which parts of the genome are accessible and which proteins bind them in immune cells, using advanced sequencing on a scale that could reveal detailed cell-by-cell information.
-
A New Way to Map DNA Structures Linked to Alzheimer's and Aging
This project is creating a new and more accurate way to map special DNA structures called R-loops, which are connected to aging and brain diseases like Alzheimer's.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.